The standard of care for weight management in 2026 is broken in a specific way: the tools are better than they have ever been, and the delivery of those tools is worse than it has ever been.
Semaglutide and tirzepatide are genuinely transformative medications. They work for most patients who are appropriate candidates. But appropriate candidacy requires a physician who has looked at your labs, reviewed your cardiovascular history, and asked the questions that a three-minute telehealth intake does not allow. At Clinic 45, that evaluation is not optional — it is the starting point.
The second problem with the current market is monitoring. Patients on GLP-1 medications are losing significant muscle mass alongside fat — a side effect that is invisible on a bathroom scale and never flagged by an app. Without periodic lab work and a body composition check, weight loss can look like success on paper while creating new metabolic problems underneath. Dr. Sleiman monitors this. Every Clinic 45 patient has documented progress data, not just a number on the scale.
The third problem is exit planning. Most weight loss programs have no plan for what happens when the medication is stopped. The evidence on GLP-1 withdrawal is clear: patients who stop without a managed taper and a metabolic maintenance strategy regain a significant portion of their weight within a year. Clinic 45 builds that exit plan into every program from the beginning.